It is likely that the emerging heterogeneity of PD-L1 expression may explain why a subset of patients with tumours expressing PD-L1+ fail to respond, while some with PD-L1– negative neoplasms respond well to checkpoint-based immunotherapies. This evidence concerns the gene CD274 and neoplasm.